Oncology Times:
doi: 10.1097/01.COT.0000333638.24797.ce
Article

Protocol Alert

Free Access
Collapse Box

Abstract

The following is a partial list of clinical trials recently added to the NCI's Physician Data Query (PDQ) database, accessible online at www.cancer.gov (Click on “Clinical Trials”).

Back to Top | Article Outline

Bladder Cancer

CA183-002, NCT00389155

First-Line Treatment of Advanced Bladder Cancer Randomized vs Gemcitabine +/− Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Age: 18 and over

Sponsor: Pharmaceutical/Industry

STUDY LEAD ORGANIZATION

Bristol-Myers Squibb Company, New York

BMS Call Center; Ph: 866-892-1BMS, ext.419

BMS Call Center outside the US and Canada; Ph: 941-906-4711, ext.419

Back to Top | Article Outline

Bone Cancer

A0081128, NCT00381095

A Study to Evaluate the Treatment of Moderate to Severe Chronic Bone Pain Related to Metastatic Cancer

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Pfizer Incorporated

Pfizer CT.gov Call Center; Ph: 800-718-1021

Back to Top | Article Outline

Brain & CNS Cancer

EF-11, NCT00379470

Effect of NovoTTF-100A in Recurrent GBM

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

NovoCure Limited

Eilon D. Kirson, MD, PhD; Ph:+972-4-8501204; Email: eilon@novo-cure.com

NABTT-0503, NCT00404248

Phase I/II Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) in Patients With Recurrent High-Grade Glioma

Age: 18 and over

Sponsor: NCI

STUDY LEAD ORGANIZATION

New Approaches to Brain Tumor Therapy

Stuart Grossman, MD, Protocol chair; Ph: 410-955-8837; Email: grossman@jhmi.edu

021-003, NCT00394628

A Phase 1b/2a Multicenter Study of AQ4N in Combination With Radiotherapy and Temozolomide, for Safety, Tolerability, and Efficacy in Subjects With Newly Diagnosed Glioblastoma Multiforme

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY ORGANIZATION

Novacea

Josephine Ford Cancer Center at Henry Ford Hospital

Ruth Ann Beasse; Ph: 313-916-3731; Email: rbeasse1@hfhs.org

CASE-CCF-4204, NCT00400816

Phase II Study of Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma

Age: 18 and over

Sponsor: Other

STUDY LEAD ORGANIZATION

Case Comprehensive Cancer Center

David Peereboom, MD, Protocol chair; Ph: 216-445-6068; Email: peerebd@ccf.org

O6BG 202, NCT00389090

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

AOI Pharmaceuticals, Incorporated

Phil Dehazya, PhD; Ph: 914-733-3445; Email: pdehazya@millennix-inc.com

Mimi Park, BS; Ph: 415-946-2422; Email: ocogtrials@ocog.net

Back to Top | Article Outline

Breast Cancer

UPCC-12199, UPCC-414500, NCT00194337

Phase II/III Study of Multimodality Breast Imaging Comprising Digital Mammography, Ultrasound, MRI, and Positron Emission Tomography in Women With Newly Diagnosed Breast Cancer

Age: 18 and over

Sponsor: NCI

STUDY LEAD ORGANIZATION

Abramson Cancer Center of the University of Pennsylvania

Abass Alavi, MD, Principal Investigator; Ph: 215-662-7238

NSABP-B-40

Phase III Randomized Study of Six Different Neoadjuvant Chemotherapy Regimens With or Without Neoadjuvant and Adjuvant Bevacizumab in Women With Operable Stages I-IIIA Breast Cancer

Age: 18 and over

Sponsor: NCI

STUDY LEAD ORGANIZATION

National Surgical Adjuvant Breast and Bowel Project

Harry Bear, MD, PhD, Protocol chair; Ph: 804-828-9325; Email: hdbear@vcu.edu

KRDI-TUM-CORE-GYN-040-380-21260, EU-20660, EUDRACT-2005-000986-20, KRDI-TUM-COR-259-PAE-0100-I, NCT00403182

Phase III Randomized Study of Chemotherapy and Endocrine Therapy as First-Line Treatment for Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

Age: Under 75

Sponsor: Other

STUDY LEAD ORGANIZATION

Klinikum Rechts Der Isar, Technische Universitaet Muenchen

Stefan Paepke, MD, Protocol chair; Ph: 49-89-4140-5433

E7389-G000-305, NCT00388726

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Eisai Inc.

Eisai Medical Services; Ph: 888-422-4743

20444, NCT00390169, CBCRA #017728

Randomized Controlled Trial Comparing MBSR to SET in Breast Cancer Patients

Age: 18 and over

Sponsor: Other

STUDY LEAD ORGANIZATION

Canadian Breast Cancer Research Alliance

British Columbia Cancer Agency, Vancouver Island Centre

Linda E. Carlson, PhD, Principal Investigator; Ph: 403-355-3209; Email: lcarlso@ucalgary.ca

BO20231, NCT00391092

A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/ Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

F. Hoffmann-La Roche, Ltd.

Dr. Luca Gianni, Principal Investigator; Ph: 973-235-5000, 800-526-6367 (for US only)

A6181064, NCT00393939

Study of Sunitinib in Combination With Docetaxel Vs Docetaxel in Patients With Advanced Breast Cancer

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORGANIZATION

Pfizer Incorporated

Pfizer CT.gov Call Center; Ph: 800-718-1021

A6181107, NCT00373113

A Clinical Trial Comparing Efficacy and Safety of Sunitinib and Capecitabine

Age: 18 and over

Sponsor: Pharmaceutical / Industry

STUDY LEAD ORANIZATION

Pfizer Incorporated

Pfizer Oncology Clinical Trial Information Service; Ph: 877-369-9753; Email: pfizercancertrials@emergingmed.com

© 2008 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share